Seven research firms currently cover Integra LifeSciences, assigning an average recommendation of “Reduce.” Among them, three have issued sell ratings, two maintain hold ratings and two grant buy ratings. Over the past year, the mean 12-month price objective stands at $15.00. Notable revisions include JPMorgan Chase & Co. raising its target from $12.00 to $13.00 while retaining an underweight recommendation, and Citigroup lowering its target from $12.00 to $11.00 alongside a sell rating.

For the quarter ended October 30, Integra reported adjusted earnings per share of $0.54, surpassing analyst consensus by $0.11. Revenue reached $402.1 million, a 5.6% year-over-year increase, though modestly below the $414.3 million consensus. Despite a negative net margin of 30.15%, the company delivered a return on equity of 14.06%. Management set Q4 guidance at $0.79–$0.84 EPS and full-year 2025 guidance at $2.19–$2.24 EPS, up from prior ranges, reflecting confidence in its neurosurgery and regenerative medicine franchises.

Director Jeffrey A. Graves acquired 9,000 shares at an average of $11.35 per share on November 5, boosting his holdings by 28.05%. Insider ownership now represents 3.54% of outstanding shares. Among institutional investors, Goldman Sachs increased its stake by 2.2% to over 1.66 million shares in Q1, while UBS Asset Management grew its position by 23.0% to 244,335 shares. Collective hedge fund adjustments indicate measured confidence, with MIRAE ASSET GLOBAL ETFS adding 5.1% and Dynamic Technology Lab establishing a new position valued at $277,000.